Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY
Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 581-582
10.1002/hon.3164_435